Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-03-21
Recursion Pharmaceuticals, Inc.
Clinical-stage biotechnology company using an AI-driven discovery stack, automated labs, and pharma partnerships to discover and develop small-molecule medicines.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Gates the Next Rerating
The upside case is a move from collaboration-funded platform story to one-product-plus-engine story. That can produce a solid multi-year revaluation, but only if 2026 turns platform promise into a credible registration path and repeatable clinical output.

Analysis

Thesis
Recursion can grow from a cash-backed platform biotech into a proof-bearing asset engine if REC-4881 earns a credible registration path and at least one follow-on program validates repeatability, turning proprietary data, lab telemetry, and collaboration economics into much higher revenue without requiring every pipeline shot to win.
Last Economy Alignment
Cheaper cognition helps because Recursion owns the data, wet-lab loop, and internal workflow where AI becomes useful, and it captures value through milestones, licenses, and royalties rather than fragile seat pricing. The score is capped by the fact that clinical and regulatory proof still decides whether that intelligence becomes durable economics.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
5.7x (from 5 most recent analyses)
Reasoning
The upside is a reclassification from cash-backed clinical-stage biotech to validated asset engine. One commercializing rare-disease asset, steadier partner milestones, and limited externalization of the platform can support a multi-bagger outcome, but I am not assuming a full speculative platform premium or broad late-stage pipeline success by 2031.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The binding risk is not whether the software works internally; it is whether REC-4881 and follow-on assets turn platform productivity into regulator-credible patient outcomes. If that proof slips, Recursion can remain a well-equipped but cash-consuming discovery company, with dilution and partner concentration overwhelming the platform narrative.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.55
They control the data, lab automation, and workflow layer that can turn cheap AI thinking into more drug ideas faster. But the market only pays if those ideas survive clinical testing and FDA scrutiny, so proof matters more than software polish.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$9.40
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case